Harte Hanks (HHS) EBITDA Margin (2010 - 2026)

Harte Hanks (HHS) has 17 years of EBITDA Margin data on file, last reported at 2.06% in Q1 2026.

• On a quarterly basis, EBITDA Margin fell 196.0% year-over-year to 2.06% in Q1 2026; TTM through Mar 2026 was 0.22%, a 115.0% decrease from a year earlier, with the FY2025 full-year figure at 0.24%, down 89.0% from the prior year.
• EBITDA Margin for Q1 2026 stood at 2.06%, down from 0.29% in the prior quarter.
• Over the last five years, EBITDA Margin for HHS reached as high as 9.47% in Q2 2022 and fell as low as 4.6% in Q4 2023.
• Historically, EBITDA Margin has averaged 3.06% across 5 years, with a median of 3.05% in 2024.
• Across the five-year window, EBITDA Margin jumped 958 bps in 2022 and sank 1262 bps in 2023, its largest moves.
• Year by year, EBITDA Margin stood at 8.02% in 2022, then tumbled by 157 bps to 4.6% in 2023, then advanced by 28 bps to 3.3% in 2024, then soared by 91 bps to 0.29% in 2025, then slumped by 602 bps to 2.06% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 2.06% in Q1 2026, 0.29% in Q4 2025, and 1.29% in Q3 2025.